Patients with endometrial cancer differ in terms of the extent of T-cell infiltration; however, the association between T-cell subpopulations and patient outcomes remains unexplored. We characterized 285 early-stage endometrial carcinoma samples for T-cell infiltrates in a tissue microarray format using multiplex fluorescent immunohistochemistry. The proportion of T cells and their subpopulations were associated with clinicopathological features and relapse-free survival outcomes. CD3+ CD4+ infiltrates were more abundant in the patients with higher grade or non-endometrioid histology. Cytotoxic T cells (CD25+, PD-1+, and PD-L1+) were strongly associated with longer relapse-free survival. Moreover, CD3+ PD-1+ stromal cells were independent of other immune T-cell populations and clinicopathological factors in predicting relapses. Patients with high stromal T-cell fraction of CD3+ PD-1+ cells were associated with a 5-year relapse-free survival rate of 93.7% compared to 79.0% in patients with low CD3+ PD-1+ fraction. Moreover, in patients classically linked to a favorable outcome (such as endometrioid subtype and low-grade tumors), the stromal CD3+ PD-1+ T-cell fraction remained prognostically significant. This study supports that T-cell infiltrates play a significant prognostic role in early-stage endometrial carcinoma. Specifically, CD3+ PD-1+ stromal cells emerge as a promising novel prognostic biomarker.
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
The datasets are available from the corresponding authors upon request.
Braun, M. M., Overbeek-Wager, E. A. & Grumbo, R. J. Diagnosis and management of endometrial cancer. Am. Fam. Physician 93, 468–474 (2016).
Colombo, N. et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Ann. Oncol. 27, 16–41 (2016).
Concin, N. et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int. J. Gynecol. Cancer 31, 12–39 (2021).
Cree, I. A., White, V. A., Indave, B. I. & Lokuhetty, D. Revising the WHO classification: female genital tract tumours. Histopathology 76, 151–156 (2020).
Cancer Genome Atlas Research, N. et al. Integrated genomic characterization of endometrial carcinoma. Nature 497, 67–73 (2013).
Kommoss, S. et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann. Oncol. 29, 1180–1188 (2018).
Talhouk, A. et al. Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer. Cancer 123, 802–813 (2017).
Liu, Y. et al. Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. J. Natl Cancer Inst. 106, dju245 (2014).
Kommoss, F. K. et al. L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile. Br. J. Cancer 119, 480–486 (2018).
Talhouk, A. et al. Molecular subtype not immune response drives outcomes in endometrial carcinoma. Clin. Cancer Res. 25, 2537–2548 (2019).
Kondratiev, S., Sabo, E., Yakirevich, E., Lavie, O. & Resnick, M. B. Intratumoral CD8+ T lymphocytes as a prognostic factor of survival in endometrial carcinoma. Clin. Cancer Res. 10, 4450–4456 (2004).
Versluis, M. A. et al. Prediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parameters. Br. J. Cancer 113, 786–793 (2015).
de Jong, R. A. et al. Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer. Gynecol. Oncol. 114, 105–110 (2009).
Piulats, J. M. et al. Molecular approaches for classifying endometrial carcinoma. Gynecol. Oncol. 145, 200–207 (2017).
Eggink, F. A. et al. Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. Oncoimmunology 6, e1264565 (2017).
Samstein, R. M. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 51, 202–206 (2019).
Guo, F., Dong, Y., Tan, Q., Kong, J. & Yu, B. Tissue infiltrating immune cells as prognostic biomarkers in endometrial cancer: a meta-analysis. Dis. Markers 1805764 (2020).
Blom, S. et al. Systems pathology by multiplexed immunohistochemistry and whole-slide digital image analysis. Sci. Rep. 7, 15580 (2017).
Pollari, M. et al. Adverse prognostic impact of regulatory T-cells in testicular diffuse large B-cell lymphoma. Eur. J. Haematol. 105, 712–721 (2020).
Ruz-Caracuel, I. et al. Myoinvasive pattern as a prognostic marker in low-grade, early-stage endometrioid endometrial carcinoma. Cancers (Basel) 11, 1845 (2019).
Autio, M. et al. Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma. Haematologica 106, 718–729 (2021).
Blom, S. et al. Fibroblast as a critical stromal cell type determining prognosis in prostate cancer. Prostate 79, 1505–1513 (2019).
Workel, H. H. et al. CD103 defines intraepithelial CD8+ PD1+ tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma. Eur. J. Cancer 60, 1–11 (2016).
Jung, I. K. et al. Tumor-infiltration of T-lymphocytes is inversely correlated with clinicopathologic factors in endometrial adenocarcinoma. Obstet. Gynecol. Sci. 57, 266–273 (2014).
Yamagami, W. et al. Immunofluorescence-detected infiltration of CD4+FOXP3+ regulatory T cells is relevant to the prognosis of patients with endometrial cancer. Int. J. Gynecol. Cancer 21, 1628–1634 (2011).
Sungu, N. et al. Expression of immunomodulatory molecules PD-1, PD-L1, and PD-L2, and their relationship with clinicopathologic characteristics in endometrial cancer. Int. J. Gynecol. Pathol. 38, 404–413 (2019).
Pasanen, A. et al. PD-L1 expression in endometrial carcinoma cells and intratumoral immune cells: differences across histologic and TCGA-based molecular subgroups. Am. J. Surg. Pathol. 44, 174–181 (2020).
Mo, Z. et al. Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer. Oncol. Lett. 12, 944–950 (2016).
Li, Z. et al. Programmed death ligand 1 expression among 700 consecutive endometrial cancers: strong association with mismatch repair protein deficiency. Int. J. Gynecol. Cancer 28, 59–68 (2018).
Xi, Z. et al. Evaluation of PTEN and CD4+FOXP3+ T cell expressions as diagnostic and predictive factors in endometrial cancer: A case control study. Med. (Baltim) 98, e16345 (2019).
Engerud, H. et al. High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer. Gynecol. Oncol. 157, 260–267 (2020).
Pages, F. et al. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 29, 1093–1102 (2010).
Barnes, T. A. & Amir, E. HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer. Br. J. Cancer 118, e5 (2018).
Horeweg, N. et al. Prognostic integrated image-based immune and molecular profiling in early-stage endometrial cancer. Cancer Immunol. Res. 8, 1508–19 (2020).
Stelloo, E. et al. Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts. Clin. Cancer Res. 22, 4215–4224 (2016).
The authors would like to thank the IdiPAZ biobank core facility for essential services support, as well as the FIMM Digital microscopy and Molecular Pathology Unit supported by HiLIFE and Biocenter Finland for the scanning.
M.M. reports having received honoraria (MSD, AstraZeneca and GSK), research grant/funding to her institution (Eisai and PharmaMar), and travel/accommodation/expenses (AstraZeneca, GSK, PharmaMar, Roche and Pfizer) outside the submitted work. O.B. reports having received honoraria (Novartis, Sanofi) outside the submitted work. A.G. reports having received honoraria (Clovis, MSD, AstraZeneca, GSK, PharmaMar and Roche) and travel/accommodation/expenses (Merck Sharp & Dohme, PharmaMar, Roche, Eisai, Pfizer, Pierre-Fabre and Tesaro-A GSK Company) outside the submitted work. A.R. reports having received honoraria and providing advisory/consultancy services (MSD, AstraZeneca, Roche, GSK, Clovis, PharmaMar, Lilly, Amgen), as well as having received research grant/funding to his institution (Eisai, PharmaMar, Roche), travel/accommodation/expenses (AstraZeneca, Tesaro: A GSK Company, PharmaMar, Roche), and participating in a speakers bureau (MSD, AstraZeneca, Roche, GSK, Clovis, PharmaMar) outside the submitted work. The remaining authors declare no conflicts of interest.
The study was approved by the local ethics committee (HULP#PI3778) and was conducted in accordance with the ethical standards of the Declaration of Helsinki of the World Medical Association.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Mendiola, M., Pellinen, T., Ramon-Patino, J.L. et al. Prognostic implications of tumor-infiltrating T cells in early-stage endometrial cancer. Mod Pathol (2021). https://doi.org/10.1038/s41379-021-00930-7